SCHEMBL23488456

SCHEMBL23488456

COc1cc(OCc2ccccc2)c(Cl)cc1C(=O)N[C@H]1[C@@H](OC)O[C@H](CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
CA1 P00915 1/20 0.47
LGALS3 P17931 3/20 0.46
LGALS8 O00214 1/20 0.45
DRD4 P21917 4/20 0.43
DRD2 P14416 2/20 0.43
DRD3 P35462 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP3A4 P08684 1/20 0.43
ADRA2A P08913 1/20 0.43
CYP2D6 P10635 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
ACHE P22303 1/20 0.43
SLC6A2 P23975 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
ADRA1A P35348 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488325 0.91 CA2 (0.49) CA2CA9CA1LGALS3LGALS8
SCHEMBL23488228 0.91 CA2 (0.44) CA2CA9CA1LGALS3LGALS8
SCHEMBL23488357 0.90 CA2 (0.45) CA2CA9CA1LGALS3LGALS8
SCHEMBL23488495 0.89 CA2 (0.44) CA2CA9CA1LGALS3LGALS8
SCHEMBL23488731 0.89 CA2 (0.53) CA2CA9CA1LGALS3LGALS8
SCHEMBL23488749 0.88 CA2 (0.45) CA2CA9CA1LGALS3LGALS8
SCHEMBL23488354 0.88 CA2 (0.41) CA2CA9CA1LGALS3LGALS8
SCHEMBL23488535 0.87 CA1 (0.55) CA2CA9CA1LGALS3LGALS8
SCHEMBL23488312 0.86 CA2 (0.47) CA2CA9CA1LGALS3LGALS8
SCHEMBL23488706 0.86 CA2 (0.47) CA2CA9CA1LGALS3LGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 CA2 1099/4885CA9 906/4885CA1 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.